What IS being presented at ASCO this year

Over the next few days we plan to work our way through the abstracts for the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) , which were made available on line yesterday, and let you know what studies look to be of interest.

The following is the first of several groups of 15 prostate cancer-related studies that is being presented on site in Orlando. The authors and titles of what appear to be the more important papers have been highlighted:

  • Drewnowska et al. (“PCA3: a urine-based genetic assay for detection of prostate cancer in men with elevated PSA”) report that the PCA3 test is significantly more specific for the detection of prostate cancer compared to serum PSA.
  • Liu et al. (“Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists”) report that continued expression of LHRH pituitary receptors supports the concept of targeting prostatic LHRH receptors to deliver cytotoxic therapy based on LHRH analogs.
  • Fryzek et al. (“The prognostic significance of bone metastases and skeletal-related events (SREs) in prostate cancer survival: a population-based historical cohort study in Denmark [1999-2007]”) conclude that although the presence of bone metastases confers a short-term prognosis in prostate cancer patients, survival is even poorer for patients who also experience skeletal-related complications.
  • Abedi et al. (“Phase I trial of anti-PSMA designer T-cell autografting in prostate cancer”) will provide an update on Phase I data from their study of a new approach to adoptive immune therapy in metastatic prostate cancer.
  • Hayes et al. (“Short-course androgen suppression therapy prior to brachytherapy for favorable-risk prostate cancer and the risk of all-cause mortality in men with or without preexisting cardiovascular disease“) report that a pre-existing cardiovascular condition is associated with an increased risk of death in men with favorable-risk prostate cancer treated with short-course androgen deprivation prior to brachytherapy.
  • Turaka et al. (“Correlation of hypoxic prostate/muscle pO2 (P/M PO2) ratio and biochemical failure in patients with localized prostate cancer: Long-term results.”) have shown that tumor hypoxia may predict poor long-term biochemical outcomes following prostate brachytherapy.
  • Stephenson et al. (Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy“) have developed and validated a nomogram predicting the 15-year prostate cancer-specific mortality of men following radical prostatectomy, and suggesting that data from other biomarkers add little to the accuracy of this nomogram.
  • Purnell et al. (“Cancer-related self-efficacy in African American prostate cancer patients compared to whites”) report that, compared to Caucasian men, African American men appear to have less confidence in their ability to cope with prostate cancer following diagnosis.
  • D’Amico et al. (“Diabetes and the risk of death in men with favorable or high-risk prostate cancer following radiation therapy“) comment on the importance of aggressive management of diabetes in diabetic men with low-risk prostate cancer in order to minimize risks for diabetes-associated mortality following radiation therapy.
  • Oh et al. (“A Phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients [pts] with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial“) will report updated results on the effectiveness and safety of neoadjuvant docetaxel + bevacizumab in patients with high-risk, localized prostate cancer.
  • Kolevska et al. (“Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer [HRPC]“) will report updated results of the use of an albumin-bound, nanoparticular formulation of paclitaxel as first line chemotherapy for treatment of men with hormone-refractory prostate cancer.
  • Vourganti et al. (“Evaluation of the prostate-specific antigen/solvent interaction analysis [PSA/SIA] assay for prostate cancer [CaP] diagnosis”) claim that PSA/SIA has greater specificity that PSA levels alone in determining the need for a prostate biopsy.
  • Lu-Yao et al. (“Outcomes of conservatively managed localized prostate cancer“) report that patients of > 65 years of age diagnosed with T1/2 prostate cancer in the PSA era are at significantly lower risk for prostate cancer-specific death within 10 years than was the case in the pre-PSA era.
  • Glode et al. (“Southwest Oncology Group S9921: prolonged event-free survival in high-risk prostate cancer [PC] patients receiving adjuvant androgen deprivation”) report preliminary, non-comparative data from SWOG9921 indicating markedly low PSA relapse and death rates in high risk prostate cancer patients treated with combined androgen blockade in this trial.
  • Scher et al. (“Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer [CRPC]“) will report the latest available data from the 140 patients enrolled in this early trial of MDV3100 for the treatment of CRPC.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: